For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

ARA-290

Also known as: Cibinetide

ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide derived from the helix-B surface of erythropoietin (EPO), developed by Araim Pharmaceuticals. It selectively activates the innate repair receptor (IRR) for anti-inflammatory, tissue-protective, and neuroprotective signaling without stimulating erythropoiesis. ARA-290 is not FDA-approved; it has received FDA Fast Track and Orphan Drug designations for sarcoidosis-associated small fiber neuropathy and remains in clinical development as of April 2026.

Where to buy · live market data

Who's worth your money for ARA-290

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 17 scored sellers

$5.00/mg

$49.99 · 10mg · 100.0% purity

2 COAs
Buy Code MERIT · 10% off

Best value after code

$3.09/mg effective with 10% code

$3.43/mg

$54.95 · 16mg · 99.0% purity

1 COA
Buy Code Meritverified · 10% off

Most tested

8 independent COAs on file

$3.81/mg

$61.00 · 16mg · 99.6% purity

Average price

$6.13/mg

Sellers

47

45-day trend

-11%

33 of 47 sellers have a current price· 13 stale hidden· 3 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch ARA-290

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About ARA-290

CAS

1208243-50-8

Molecular formula

C51H84N16O21

Sequence

UEQLERALNSS

Typical dose range

4 mg/day subcutaneous (clinical trial dosing for diabetic neuropathy and sarcoidosis-associated small fiber neuropathy)

Half-life

~20 minutes terminal half-life (after 4 mg SC injection; biological effect may persist 24–72 hours)

Independent evidence

COAs for ARA-290

65 third-party tests across 23 vendors. Each card links to the full report.

All 65 COAs for ARA-290 →
Measured purity 98.2%–100.0% across 49 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.93 %
Sep 2026
ILS Labs Strong

For

Ara-290

by Hydro Research Peptides· batch HR-2026-1256

✓ Vendor-published
99.60 %
Sep 2026
Janoshik Analytical Limited

For

ARA-290

by Verified Peptides· batch ARA1026041D

COA on file
Aggregated · 3rd-party listing
99.97 %
Aug 2026
Janoshik Analytical Limited

For

ARA-290

by Longeva· batch B-2026-ARA-290-10-002

Aggregated · 3rd-party listing
99.30 %
Aug 2026
Freedom Diagnostics Moderate

For

ARA-290

by Novaglo Research· batch 2001081226ARA

Aggregated · 3rd-party listing
99.00 %
Jul 2026
Ethos Analytics Strong

For

ARA-290

by OROS Research· batch OR-LPARA32-726-B2

Aggregated · 3rd-party listing
99.73 %
Jul 2026
Freedom Diagnostics Moderate

For

ARA-290

by Novaglo Research· batch 11016672026AR

Aggregated · 3rd-party listing
99.92 %
Jul 2026
Kovera Labs

For

ARA-290

by Synthesis Peptides· batch ARA10826

Aggregated · 3rd-party listing
99.73 %
Jul 2026
ILS Labs Strong

For

ARA-290

by Ion Peptide· batch RA10-06172026

✓ Vendor-published
99.80 %
Jul 2026
ILS Laboratories

For

ARA-290

by Ion Peptide· batch RA10-06172026

COA on file
✓ Vendor-published
99.92 %
Jun 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch RA16-06242026

COA on file
Aggregated · 3rd-party listing
99.92 %
Jun 2026
Freedom Diagnostics Moderate

For

ARA-290

by Ion Peptide· batch RA16-06242026

Aggregated · 3rd-party listing
99.32 %
Jun 2026
Kovera Labs

For

ARA-290

by Real Peptides· batch BATCH-0322

Aggregated · 3rd-party listing
99.83 %
Jun 2026
Janoshik Analytical Limited

For

ARA-290

by EZ Peptides· batch EZP-ARA1005192026-03

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

ARA-290

by OROS Research· batch OR-LPARA32-526-B1

✓ Vendor-published
99.83 %
Jun 2026
Janoshik Analytical Limited

For

ARA-290

by EZ Peptides· batch EZP-ARA1005192026-03

COA on file
Aggregated · 3rd-party listing
99.43 %
May 2026
ILS Labs Strong

For

Ara-290

by Ion Peptide· batch ARA16-05202026

✓ Vendor-published
99.43 %
May 2026
ILS Laboratories

For

Ara-290

by Ion Peptide· batch ARA16-05202026

COA on file
Aggregated · 3rd-party listing
99.23 %
Apr 2026
ILS Labs Strong

For

ARA-290

by Riptide Wellness· batch RWARA-10-1002

Aggregated · 3rd-party listing
98.37 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

ARA-290

by Verified Peptides· batch ARA04260312C

✓ Vendor-published
98.37 %
Apr 2026
Janoshik Analytical Limited

For

ARA-290

by Verified Peptides· batch ARA0426031 2C

COA on file
Aggregated · 3rd-party listing
99.97 %
Mar 2026
Kovera Labs

For

ARA-290

by Glacier Aminos· batch ARA10GA-01

Aggregated · 3rd-party listing
99.47 %
Mar 2026
Janoshik Analytical Limited

For

ARA-290

by Peptide Crafters· batch PC-G1-AR16

Aggregated · 3rd-party listing
99.41 %
Feb 2026
Freedom Diagnostics Moderate · HPLC

For

ARA-290

by Peptide Supply Co.· batch AR1022026

Aggregated · 3rd-party listing
99.12 %
Feb 2026
Freedom Diagnostics Moderate

For

ARA-290

by Modern Research Peptides· batch LCHK262

Research depth

16 citations indexed for ARA-290

All research on ARA-290 →

animal · 2026

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice

Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable.

case-report · 2026

Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases

Inferior alveolar nerve (IAN) injury represents a substantial complication in oral and maxillofacial surgery, often leading to persistent neurosensory dysregulation with limited effective treatment options.

animal · 2022

Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression

Alzheimer's disease (AD) pathology is characterized by amyloid-β (Aβ) deposition and tau hyper-phosphorylation, accompanied by a progressive cognitive decline. Monocytes have been recently shown to play a major role in modulating Aβ pathology, and thereby have been pointed as potential therapeutic targets.

animal · 2021

Synthesis and evaluation of <sup>99m</sup>Tc-DOTA-ARA-290 as potential SPECT tracer for targeting cardiac ischemic region

Objectives Myocardial infarction caused by ischemia of heart tissue is the main reason for death worldwide; therefore, early detection can reduce mortality and treatment costs.

animal · 2016

A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets

Background Erythropoietin exerts anti-inflammatory, antiapoptotic, and cytoprotective effects in addition to its hematopoietic action. A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties.

Study · 2016

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception

ARA 290 is an erythropoietin-derived polypeptide that possesses analgesic and tissue protective effect in many diseases such as diabetes and cancer.